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Introduction: There is a clear correlation between small airways dysfunction and poor 
clinical outcomes in patients with chronic obstructive pulmonary disease (COPD), and it is 
therefore important that inhalation therapy (both bronchodilator and anti-inflammatory) can 
deposit in the small airways. Two single-inhaler triple therapy (SITT) combinations are 
currently approved for the maintenance treatment of COPD: extrafine formulation beclometha-
sone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB), and non- 
extrafine formulation fluticasone furoate/vilanterol/umeclidinium (FluF/VI/UMEC). This 
study evaluated the lung deposition of the inhaled corticosteroid (ICS), long-acting β2-agonist 
(LABA), and long-acting muscarinic antagonist (LAMA) components of these two SITTs.
Materials and Methods: Lung deposition was estimated in-silico using functional respira-
tory imaging, a validated technique that uses aerosol delivery performance profiles, patients’ 
high-resolution computed tomography (HRCT) lung scans, and patient-derived inhalation 
profiles to simulate aerosol lung deposition.
Results: HRCT scan data from 20 patients with COPD were included in these analyses, who 
had post-bronchodilator forced expiratory volume in 1 second (FEV1) ranging from 19.3% to 
66.0% predicted. For intrathoracic deposition (as a percentage of the emitted dose), deposi-
tion of the ICS component was higher from BDP/FF/GB than FluF/VI/UMEC; the two triple 
therapies had similar performance for both the LABA component and the LAMA compo-
nent. Peripheral deposition of all three components was higher with BDP/FF/GB than FluF/ 
VI/UMEC. Furthermore, the ratios of central to peripheral deposition for all three compo-
nents of BDP/FF/GB were <1, indicating greater peripheral than central deposition (0.48 
±0.13, 0.48±0.13 and 0.49±0.13 for BDP, FF and GB, respectively; 1.96±0.84, 0.97±0.34 and 
1.20±0.48 for FluF, VI and UMEC, respectively).
Conclusions: Peripheral (small airways) deposition of all three components (ICS, LABA, 
and LAMA) was higher from BDP/FF/GB than from FluF/VI/UMEC, based on profiles from 
patients with moderate to very severe COPD. This is consistent with the extrafine formula-
tion of BDP/FF/GB.
Keywords: tomography, X-ray computed, metered dose inhalers, dry powder inhalers, 
inhaled corticosteroid, long-acting beta2 agonist, long-acting muscarinic antagonist
Introduction
The small (or peripheral) airways, defined as those with a diameter <2 mm, are the 
major site of airflow obstruction in all severities of COPD,1,2 with a loss in terminal 
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bronchioles and a decrease in alveolar surface area even in 
patients with mild airflow obstruction.2 However, small 
airways dysfunction (SAD) cannot be detected through 
standard spirometry, and so may go unnoticed (the so- 
called “quiet zone”3). This is important, as there is 
a clear correlation between the presence of SAD and 
increased decline in forced expiratory volume in 1 second 
(FEV1) in patients with COPD.4 Further, SAD can be 
a precursor to the development of emphysema, such that 
treatments targeting the small airways could potentially 
reduce emphysema progression.1 In addition, increased 
gas trapping (which is used as a surrogate of SAD) corre-
lates with a number of clinical outcomes in patients with 
COPD, including decreased six-minute walking distance, 
increased exacerbation frequency, and worse health status 
and dyspnea.5 Furthermore, small airways resistance 
(another marker of SAD) correlates with worsening health 
status in COPD.6 Therefore, the ability of a molecule to 
deposit in the small airways is an important aspect of 
therapy selection (both bronchodilator and anti-inflamma-
tory) for patients with COPD.7,8
The most important determinant of inhaled drug lung 
delivery is particle size.9 Extrafine particles (mass median 
aerodynamic diameter, MMAD <2 μm10) in aerosolized 
medicines are more able to consistently reach small air-
ways than non-extrafine particles,11–13 with resulting 
enhanced drug delivery to these areas, improved overall 
lung deposition, and lower deposition in the oropharynx.14 
In turn, lower oropharyngeal deposition decreases the 
potential for local side effects and systemic absorption.8
For patients with COPD who either experience exacer-
bations despite a long-acting β2-agonist (LABA) plus 
a long-acting muscarinic antagonist (LAMA) or experi-
ence symptoms or exacerbations despite an inhaled corti-
costeroid (ICS) plus a LABA, inhaled triple therapy with a 
triple combination of an ICS, a LABA and a LAMA is 
recommended.15 Two single-inhaler triple ICS/LABA/ 
LAMA combinations are currently approved for the main-
tenance treatment of COPD in several countries around the 
world. One consists of extrafine formulation beclometha-
sone dipropionate/formoterol fumarate/glycopyrronium 
bromide (BDP/FF/GB) delivered via pressurized metered 
dose inhaler (pMDI). The other consists of non-extrafine 
formulation fluticasone furoate/vilanterol/umeclidinium 
(FluF/VI/UMEC) delivered via dry powder inhaler (DPI).
The current study’s aim was to evaluate the lung 
deposition of these two single inhaler triple therapies. 
Evaluations were performed using functional respiratory 
imaging (FRI), which is a validated computational fluid 
dynamics (CFD)-based technique that uses aerosol deliv-
ery performance profiles, patients’ high-resolution com-
puted tomography (HRCT) lung scans, and patient- 




The FRI technique has been previously described and 
validated,16 and a number of studies have confirmed the 
good consistency between FRI and scintigraphy.17–29 FRI 
is based on four components: (1) patient-specific 3-D air-
way geometry modelling; (2) inhaler characteristics; (3) 
inhalation profile; and (4) CFD simulations to model lung 
deposition.
No patients were recruited for this study: 3-D geome-
tries of the airways and lungs from patients with COPD who 
had airflow limitation ranging from moderate to very severe 
were obtained from the FLUIDDA database, selected to 
include appropriate age and height ranges. These patient- 
specific models included the extrathoracic region (compris-
ing the mouth and upper airways) and intrathoracic airways. 
The analyses presented in this manuscript focus on the 
intrathoracic airways, which were divided into: the central 
airways, from the start of the trachea and including all the 
airways visible on a HRCT scan; and the peripheral (ie, 
small) airways.
Segmentation and 3D model operations were per-
formed in commercially available validated software 
packages (Mimics 20.0 and 3-Matic 12.0, Materialise nv, 
Belgium). Segmentation was automatic, with airways then 
manually checked and missing branches added. HRCT 
scans were acquired retrospectively, with informed con-
sent obtained from each patient, and ethical approval 
granted by the Ethics Committee of the University 
Hospital in Antwerp, Belgium. HRCT scans were also 
used to generate models for each of the investigated 
devices, with the device geometry reverse engineered 
from the HRCT into a 3D computer-aided design model, 
and then virtually coupled to patients’ airway models.
Intrathoracic deposition of the ICS, LABA and LAMA 
components were calculated for each inhaler. For both 
devices, inhalation profiles were constructed based on retro-
spective patient data from two other sets of patients (differ-
ent to those from whom the 3-D airways geometries were 
obtained). For BDP/FF/GB (delivered through a pMDI), 
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average flow rates ranged from 16 to 68 L/min; for FluF/VI/ 
UMEC (delivered through a DPI), average flows were 
between 30 and 90 L/min (the differences in flows due to 
differences in the instructions for correct device use). Two 
inhalation flow profiles were randomly assigned to each 
patient model, with every patient model assigned one low 
flow profile (mean 44 L/min [range 35–61 L/min]) and one 
high flow profile (77 [59–94] L/min). Flows were not age- 
adjusted, and it was assumed that the inhalers were used 
correctly with no inhalation errors. All particles that are 
inhaled were assumed to deposit, with no-slip conditions 
chosen for the airway walls, ie, particles are trapped when 
they hit the wall. In addition, particles not deposited in 
either the extrathoracic or central airways were considered 
to be deposited in the peripheral airways.
Statistical Methods
All statistical analyses were conducted using R version 
3.2.5 or higher. To investigate statistical equivalence for 
the deposition patterns, a two-one-sided t-test, with 
equivalence bounds set to [0.8, 1.25], was used to assess 
paired differences per lung region. According to the US 
Food and Drug Administration Guidance for Industry on 
Statistical Approaches to Establishing Bioequivalence, the 
calculated confidence interval of the ratio Test over 




HRCT scan data from 20 patients with COPD were 
included in these analyses (Table 1).
Outcomes
For total intrathoracic drug deposition (ie, central plus 
peripheral) expressed as a percentage of the emitted 
dose, deposition of the ICS component was higher from 
BDP/FF/GB (35.9±6.7%) than FluF/VI/UMEC (23.3 
±4.6%), whereas the two triple therapies had similar per-
formance for the LABA component (36.7±6.8% and 34.8 
±4.5%) and for the LAMA component (35.5±6.5 and 35.0 
±5.3%; Figure 1). However, peripheral drug deposition of 
all three components was higher with BDP/FF/GB than 
with FluF/VI/UMEC (ICS: 24.5±5.1 and 8.6±3.0; LABA: 
25.0±5.3 and 18.2±3.9; LAMA: 24.1±5.1 and 16.8±4.9; 
Figure 2). These results were supported by the analysis of 
statistical equivalence, in which the intrathoracic and per-
ipheral depositions of the ICS component of BDP/FF/GB 
(ie, BDP) were both significantly higher than that of the 
ICS component of FluF/VI/UMEC (Figure 3). For the 
LABA component, whereas intrathoracic deposition met 
the definition of equivalence, the upper confidence interval 
of peripheral deposition difference exceeded 1.25 and the 
confidence interval did not include 1, indicating greater 
deposition of this component from BDP/FF/GB. Similarly, 
for the LAMA component, intrathoracic deposition met 
the definition of equivalence, but the upper confidence 
interval of peripheral deposition difference exceeded 1.25 
and the confidence interval did not include 1, indicating 
greater deposition of this component from BDP/FF/GB. 
Furthermore, the ratio of central to peripheral deposition 
for all three components of BDP/FF/GB were below 1, 
indicating greater deposition in the peripheral airways than 
the central airways (Table 2). The central-to-peripheral 
ratio increased slightly with GOLD Grade for some of 
the molecules (Table 2). This implies that the more severe 
the airflow limitation is, the more drug deposits in the 
central region – although the trend to greater peripheral 
than central deposition of all three components of BDP/ 
FF/GB was unaltered.
One additional advantage of the FRI technique is that it 
permits a visualization of lung deposition. As can be seen 
in Figure 4, deposition from BDP/FF/GB was widespread 
throughout all areas of the lung. In contrast, there was 
limited peripheral deposition from FluF/VI/UMEC.
Discussion
These analyses, using computer simulations, demonstrated 
that the extrafine formulation of BDP/FF/GB provided 
greater peripheral (small airways) than central deposition. 
Table 1 Characteristics of Patients Providing HRCT Scan Data
Parameter Patients (N=20)
Male, n (%) 15 (75.0)
Age, years 64.0±7.68 (44–77)
Height, cm 168.9±8.40 (158–188)
Smoking history, pack-years 51.3±29.5 (25–110)
Post-bronchodilator FEV1 predicted 42.3±14.8 (19.3–66.0)
50–80%, n (%) 7 (35.0)
30–50%, n (%) 8 (40.0)
<30%, n (%) 5 (25.0)
Post-bronchodilator FEV1 to FVC ratio 0.41±0.14 (0.17–0.62)
Note: Data are mean±SD (range) unless specified otherwise. 
Abbreviations: FEV1, forced expiratory volume in 1 sec; FVC, forced vital 
capacity.
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In addition, the relative deposition patterns are interesting. 
Overall intrathoracic deposition of the LABA and LAMA 
components were similar for BDP/FF/GB and FluF/VI/ 
UMEC. In contrast, a significantly higher proportion of 
the ICS component was deposited in the intrathoracic 
region for BDP/FF/GB than was the case for FluF/VI/ 
UMEC. This could have potential tolerability benefits, in 
that it suggests lower extrathoracic deposition of the ICS 
component of BDP/FF/GB – ie, lower deposition in the 
mouth and upper airways, typically associated with the 
local adverse effects of ICS preparations, including oral 
candidiasis and hoarse voice.15 This would require further 
verification in real-world settings or in comparative rando-
mized controlled trials. Importantly, peripheral distribution 
of all three components of BDP/FF/GB was higher than that 
of the three components of FluF/VI/UMEC (with consistent 
deposition for all three components), with the ratio of cen-
tral to peripheral deposition clearly indicating greater pre-
ferential deposition to the small airways of all three 
components of BDP/FF/GB – especially for the ICS com-
ponent. This higher peripheral deposition has potential clin-
ical advantages, not only as this is the major site of airflow 
obstruction in COPD,1,2 but given the surface area of the 
peripheral airways is greater than that of the central 
airways.9 One potential explanation for this deposition pat-
tern is the extrafine formulation of BDP/FF/GB, given that 
other studies have shown the ability of such particles to 
consistently reach, and deposit in, the small airways.11,14 In 
contrast, the deposition pattern of the three components of 
FluF/VI/UMEC varied, with almost equal central and 
Figure 1 Intrathoracic deposition as percentage of delivered dose for BDP/FF/GB and FluF/VI/UMEC. Data in brackets on the x-axis are mean ± standard deviation. The 
extremes of the box represent the quartiles, the black line gives the median, and the whiskers indicate the range.  
Abbreviations: BDP/FF/GB, beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide; FluF/VI/UMEC, fluticasone furoate/vilanterol/umeclidinium; ICS, 
inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.
Figure 2 Peripheral airway deposition of delivered dose for BDP/FF/GB and FluF/VI/UMEC. Data in brackets on the x-axis are mean ± standard deviation. The extremes of 
the box represent the quartiles, the black line gives the median, and the whiskers indicate the range.  
Abbreviations: BDP/FF/GB, beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide; FluF/VI/UMEC, fluticasone furoate/vilanterol/umeclidinium; ICS, 
inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.
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peripheral deposition for the LABA and LAMA compo-
nents, whereas the ICS component was nearly twice as 
likely to deposit centrally than peripherally.
The small airways are difficult to assess directly, espe-
cially using standard spirometry – with FEV1 not properly 
reflecting small airways abnormalities. A range of indirect 
measures have therefore been employed, including gas 
trapping and impulse oscillometry.31 FRI was developed 
to use standard HRCT equipment together with computer 
modelling, with no specialized equipment or techniques 
required, and so could potentially be a useful tool both in 
clinical trials and daily practice. Furthermore, as we 
demonstrated in these analyses, FRI permits detailed 
evaluation of the deposition of the three components of 
these inhaled triple therapies – with the ability to visualize 
the lung deposition especially useful, in particular as part 
of the drug development process. Although other techni-
ques are available to assess lung deposition, such as 
gamma scintigraphy, in contrast to FRI these require spe-
cialized equipment and techniques. Despite these differ-
ences, previous studies evaluating the lung deposition of 
extrafine BDP/FF have shown similar results whether 
deposition is assessed using FRI (28%)17 or scintigraphy 
(31–34%).20,21
The study does have some limitations. First, inhalation 
was simulated from different patients than those who 
Figure 3 Normalized deposition difference for BDP/FF/GB vs FluF/VI/UMEC. Data are mean and 95% confidence interval. The dashed horizontal lines are bioequivalence 
limit of [0.8, 1.25].30  
Abbreviations: BDP/FF/GB, beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide; FluF/VI/UMEC, fluticasone furoate/vilanterol/umeclidinium; ICS, 
inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.
Table 2 Central to Peripheral Airway Deposition Ratios, Overall and by GOLD Grade. Data are Mean ± Standard Deviation, with 
Values Below 1 Indicating Greater Peripheral Than Central Deposition




GOLD Grade GOLD Grade
2 (N=7) 3 (N=8) 4 (N=5) 2 (N=7) 3 (N=8) 4 (N=5)
ICS 0.45 0.49 0.51 1.75 2.06 2.09
LABA 0.45 0.49 0.51 0.86 1.05 0.99
LAMA 0.45 0.49 0.52 1.05 1.30 1.26
Notes: GOLD Grades are: Grade 2, post-bronchodilator forced expiratory volume in 1 second 50–80% predicted; Grade 3, 30–50%; Grade 4, <30%. 
Abbreviations: BDP/FF/GB, beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide; FluF/VI/UMEC, fluticasone furoate/vilanterol/umeclidinium; ICS, 
inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
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provided the HRCT scans – and the inhalation profiles used 
for the BDP/FF/GB simulations were from different 
patients than used for the FluF/VI/UMEC simulations. 
This was for practical reasons, since inhalation profiles 
were not available for the patients whose scans were used 
in the study – and the instruction for inhalation through a 
DPI is not the same as for a pMDI, in particular due to a 
difference in flows. To get representative results, we 
selected patients with a broad range of disease severity. 
Secondly, the clinical impact (in terms of both efficacy 
and tolerability) of the higher peripheral deposition of triple 
ICS/LABA/LAMA therapy in COPD has not been evalu-
ated – and indeed there are no head-to-head studies of these 
two triple therapies. A number of systematic literature 
reviews and meta-analyses have been published which 
attempt indirect comparisons of triple therapies in patients 
with COPD (either single- or multiple-inhaler); in these 
evaluations the effects of triple therapies seem broadly 
consistent, but are hindered by differences in study design 
and the populations recruited.32–34 Thirdly, as data were 
obtained from a database with no patients specifically 
recruited for the study, data on their disease characteristics 
are limited to lung function, and we have no information on 
their medication. Finally, this study involved two different 
sets of molecules, delivered from two different inhaler 
types, and so comparisons should be made with care. 
However, when selecting therapies for COPD, the choice 
of inhaler device has to be individually tailored, depending 
on a patient’s ability and preference.15,35 Indeed, the use of 
extrafine triple therapy has translated into clinical benefits 
in randomized controlled trials of patients with COPD.36–39 
In this respect, the ability of inhaled molecules to target the 
peripheral airways is an important additional consideration 
when selecting a therapy.
Conclusions
Peripheral (small airways) deposition of all three compo-
nents (ICS, LABA, and LAMA) was higher from BDP/FF/ 
GB than from FluF/VI/UMEC, using FRI simulations 
based on profiles from patients with moderate to very 
severe COPD. This is consistent with the extrafine particle 
size formulation of BDP/FF/GB.
Data Sharing Statement
Chiesi commits to sharing with qualified scientific and 
medical researchers, conducting legitimate research, 
patient-level data, study-level data, the clinical protocol 
and the full clinical study report of Chiesi Farmaceutici 
S.p.A.-sponsored interventional clinical trials in patients 
for medicines and indications approved by the European 
Medicines Agency and/or the US Food and Drug 
Administration after 1st January 2015, following the 
approval of any received research proposal and the signa-
ture of a Data Sharing Agreement. Chiesi provides access 
to clinical trial information consistently with the principle 
of safeguarding commercially confidential information and 
patient privacy. Other information on Chiesi’s data sharing 
commitment, access and research request’s approval pro-
cess is available in the Clinical Trial Transparency section 
of http://www.chiesi.com/en/research-and-development/.
Figure 4 Visualization of deposition in entire respiratory airways of BDP/FF/GB (left hand panel) and FluF/VI/UMEC (right hand panel) (all components, all flow rates). The 
bright yellow color indicates greater deposition.  
Abbreviations: BDP/FF/GB, beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide; FluF/VI/UMEC, fluticasone furoate/vilanterol/umeclidinium.
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